186 related articles for article (PubMed ID: 1868045)
1. Phase II trial of high-dose interleukin-2 and lymphokine-activated killer cells in Hodgkin's disease and non-Hodgkin's lymphoma.
Margolin KA; Aronson FR; Sznol M; Atkins MB; Ciobanu N; Fisher RI; Weiss GR; Doroshow JH; Bar MH; Hawkins MJ
J Immunother (1991); 1991 Jun; 10(3):214-20. PubMed ID: 1868045
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-2 lymphokine-activated killer cell therapy of non-Hodgkin's lymphoma and Hodgkin's disease.
Bernstein ZP; Vaickus L; Friedman N; Goldrosen MH; Watanabe H; Rahman R; Arbuck SG; Sweeney J; Vesper D; Henderson ED
J Immunother (1991); 1991 Apr; 10(2):141-6. PubMed ID: 2043594
[TBL] [Abstract][Full Text] [Related]
3. The use of interleukin-2 and lymphokine-activated killer cells for the treatment of patients with non-Hodgkin's lymphoma.
Weber JS; Yang JC; Topalian SL; Schwartzentruber DJ; White DE; Rosenberg SA
J Clin Oncol; 1992 Jan; 10(1):33-40. PubMed ID: 1727923
[TBL] [Abstract][Full Text] [Related]
4. Phase II trials of high-dose interleukin-2 and lymphokine-activated killer cells in advanced breast carcinoma and carcinoma of the lung, ovary, and pancreas and other tumors.
Sparano JA; Fisher RI; Weiss GR; Margolin K; Aronson FR; Hawkins MJ; Atkins MB; Dutcher JP; Gaynor ER; Boldt DH
J Immunother Emphasis Tumor Immunol; 1994 Oct; 16(3):216-23. PubMed ID: 7834121
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-2 therapy with or without lymphokine-activated killer-cell infusions for low-grade non-Hodgkin's lymphomas?
Levy R; Tourani JM; Andrieu JM
J Clin Oncol; 1992 Aug; 10(8):1366. PubMed ID: 1634929
[No Abstract] [Full Text] [Related]
6. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.
Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Gaynor ER; Boldt DH; Doroshow JH; Bar MH
J Clin Oncol; 1992 Feb; 10(2):275-81. PubMed ID: 1732429
[TBL] [Abstract][Full Text] [Related]
7. IL-2 treatment after autologous bone marrow transplantation in poor prognosis Hodgkin's disease: defective IL-2-induced LAK activity?
Tiberghien P; Racadot E; Fest T; Lioure B; Pariset J; Delain M; Voillat L; Flesch M; Amsallem D; Plouvier E
Bone Marrow Transplant; 1991; 7 Suppl 2():145. PubMed ID: 1878686
[No Abstract] [Full Text] [Related]
8. Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen.
Clark JW; Smith JW; Steis RG; Urba WJ; Crum E; Miller R; McKnight J; Beman J; Stevenson HC; Creekmore S
Cancer Res; 1990 Nov; 50(22):7343-50. PubMed ID: 2224862
[TBL] [Abstract][Full Text] [Related]
9. [Lymphokine-activated killer (LAK) cells and interleukin-2 (IL-2) therapy that improved lymphadenopathy in a patient with B cell non-Hodgkin's lymphoma].
Nakata K; Ogawa R; Wake A; Sato T; Nagata K; Mori N; Tsukada J; Misago M; Zeki K; Morimoto I
Rinsho Ketsueki; 1992 Feb; 33(2):205-10. PubMed ID: 1635170
[TBL] [Abstract][Full Text] [Related]
10. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer.
Rosenberg SA; Lotze MT; Yang JC; Topalian SL; Chang AE; Schwartzentruber DJ; Aebersold P; Leitman S; Linehan WM; Seipp CA
J Natl Cancer Inst; 1993 Apr; 85(8):622-32. PubMed ID: 8468720
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of recombinant interleukin-2 with or without recombinant interferon-beta in non-Hodgkin's lymphoma. A study of the Cancer and Leukemia Group B.
Duggan DB; Santarelli MT; Zamkoff K; Lichtman S; Ellerton J; Cooper R; Poiesz B; Anderson JR; Bloomfield CD; Peterson BA
J Immunother (1991); 1992 Aug; 12(2):115-22. PubMed ID: 1504052
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy with interleukin 2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma: a feasibility trial.
Benyunes MC; Higuchi C; York A; Lindgren C; Thompson JA; Buckner CD; Fefer A
Bone Marrow Transplant; 1995 Aug; 16(2):283-8. PubMed ID: 7581149
[TBL] [Abstract][Full Text] [Related]
13. Toxicity and immunomodulatory effects of interleukin-2 after autologous bone marrow transplantation for hematologic malignancies.
Higuchi CM; Thompson JA; Petersen FB; Buckner CD; Fefer A
Blood; 1991 Jun; 77(12):2561-8. PubMed ID: 2043762
[TBL] [Abstract][Full Text] [Related]
14. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
Sznol M; Clark JW; Smith JW; Steis RG; Urba WJ; Rubinstein LV; VanderMolen LA; Janik J; Sharfman WH; Fenton RG
J Natl Cancer Inst; 1992 Jun; 84(12):929-37. PubMed ID: 1629914
[TBL] [Abstract][Full Text] [Related]
15. Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma.
Horning SJ; Negrin RS; Chao JC; Long GD; Hoppe RT; Blume KG
J Clin Oncol; 1994 Dec; 12(12):2552-8. PubMed ID: 7989928
[TBL] [Abstract][Full Text] [Related]
16. A phase I trial of recombinant interleukin-2 combined with recombinant interferon-gamma in patients with cancer.
Redman BG; Flaherty L; Chou TH; al-Katib A; Kraut M; Martino S; Chen B; Kaplan J; Valdivieso M
J Clin Oncol; 1990 Jul; 8(7):1269-76. PubMed ID: 2113571
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of involved-field radiotherapy preceding autologous stem cell transplantation for patients with high-risk lymphoma or Hodgkin's disease.
Dawson LA; Saito NG; Ratanatharathorn V; Uberti JP; Adams PT; Ayash LJ; Reynolds CM; Silver SM; Schipper MJ; Lichter AS; Eisbruch A
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):208-18. PubMed ID: 15093918
[TBL] [Abstract][Full Text] [Related]
18. Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV).
Wheeler C; Khurshid A; Ibrahim J; Elias A; Mauch P; Ault K; Antin J
Leuk Lymphoma; 2001 Feb; 40(5-6):499-509. PubMed ID: 11426523
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma.
Dutcher JP; Gaynor ER; Boldt DH; Doroshow JH; Bar MH; Sznol M; Mier J; Sparano J; Fisher RI; Weiss G
J Clin Oncol; 1991 Apr; 9(4):641-8. PubMed ID: 2066760
[TBL] [Abstract][Full Text] [Related]
20. Time-course of the recovery of cellular immune function after high-dose chemotherapy and peripheral blood progenitor cell transplantation for high-grade non-Hodgkin's lymphoma.
Scheid C; Pettengell R; Ghielmini M; Radford JA; Morgenstern GR; Stern PL; Crowther D
Bone Marrow Transplant; 1995 Jun; 15(6):901-6. PubMed ID: 7581089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
